Instant Allergenicity Prediction for Novel Proteins

Bringing a novel protein to market—like a plant-based meat alternative or a new dairy substitute—requires extensive safety testing. Traditional allergenicity assessment is a manual, multi-month process involving sequence alignment and animal studies. Our AI model provides an instant, high-confidence prediction of cross-reactivity with known allergens, allowing your R&D team to screen thousands of candidates in silico before committing to costly wet-lab validation. This shifts risk identification from Phase 3 to the design phase, preventing costly late-stage failures and accelerating time-to-market by 6-12 months.

For therapeutic proteins, unexpected immunogenicity can derail clinical trials and endanger patients. Our platform integrates bio-informatics AI to analyze protein structure, epitope mapping, and population-level HLA binding affinities in seconds. This enables pharmaceutical teams to:

• Prioritize lead candidates with the lowest predicted risk of adverse immune reactions.
• Design safer next-generation biologics and biosimilars by engineering out problematic regions.
• Build stronger regulatory submissions with computational evidence of safety-by-design, satisfying FDA and EMA expectations for early risk assessment.

Navigating the patchwork of global regulations (EFSA, FDA, FSANZ) for novel foods is a major bottleneck. Our AI acts as a continuous compliance engine, benchmarking protein designs against evolving regulatory databases and scientific literature. It provides audit-ready reports that document the decision logic for allergenicity predictions, directly supporting GRAS (Generally Recognized as Safe) determinations and Novel Food applications. This transforms a reactive, document-heavy process into a proactive, integrated part of the development workflow.

Companies using microbial hosts to produce proteins face unique challenges: even minor sequence variations in expression systems can alter final product conformation and safety. Our real-time prediction tool is integrated into the design-build-test-learn cycle, allowing synthetic biologists to iteratively tweak sequences and immediately assess the allergenicity impact. This enables rapid optimization of yield, stability, and safety simultaneously, turning a sequential trade-off into a parallel optimization problem and maximizing the commercial potential of each engineered strain.

In the age of clean-label demand, consumers and retailers demand proof of safety. Our technology enables brands to move beyond vague claims to data-backed transparency. By leveraging AI that explains why a protein is predicted to be low-risk, companies can create compelling, science-first marketing narratives. This builds a formidable competitive moat and strengthens brand equity, turning a regulatory hurdle into a market differentiation point that resonates with safety-conscious consumers and B2B buyers.

When evaluating acquisition targets or licensing novel protein IP, understanding the embedded safety risk is critical to valuation. Our platform provides an objective, rapid technical assessment of a target's protein portfolio. In days, not months, you can quantify potential allergenicity liabilities across their pipeline, informing negotiation strategy and post-merger integration plans. This turns a qualitative risk into a quantifiable factor, protecting against billion-dollar acquisitions burdened with unforeseen safety issues.